Please login to the form below
Phagenesis
This page shows the latest Phagenesis news and features for those working in and with pharma, biotech and healthcare.
Nestlé Health Science invests $145m in food allergy biotech
These include Nestlé's $1.9bn partnership on potential inflammatory bowel disease treatments and the acquisition of UK medical device firm and dysphagia specialist Phagenesis..
Latest news
-
Nestlé Health Science buys medical device firm
Acquisition of UK's Phagenesis expected to be completed by 2019. Nestlé Health Science is continuing to expand its interests in the broader pharma space with the acquisition of UK medical ... The staged acquisition is expected to close in 2019 but
Nestlé Health Science buys medical device firm
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Rocky start for Biogen’s Alzheimer’s drug Aduhelm
- FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer
- Gilead’s Veklury (remdesivir) cuts risk of severe COVID-19 by 87%
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- Our mission: helping patients in areas of unmet medical need
- Novo Nordisk settles US insulin pricing dispute for $100m
- Mysterious big pharma company eyes US biotech Acceleron
- COVID-19 changed change and communications will never be the same
- Understanding behaviour change: A Porterhouse Insights specialism
- Lynparza significantly delays disease progression as first-line treatment in prostate cancer
No results were found
PMHub
Spirit, an OPEN Health Company
We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...
Latest intelligence
- Understanding behaviour change: A Porterhouse Insights specialism
- ...
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
